(2)
IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 18 January 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells (the
Company ), presents an update on its activities and announces the strengthening of its financial visibility for the medium term.
Update on activities
The Company is actively pursuing the development of its main programs, currently focused primarily on THN102 and BBDF-101.
THN102 program (excessive daytime sleepiness in Parkinson s disease)
Theranexus confirms ongoing discussions with several potential partners, demonstrating the pharmaceutical industry s interest in this drug candidate, with a view to signing an agreement by the end of the first half of 2021 which will pave the way for the next stages in the clinical development of THN102 in Parkinson s disease. Theranexus is continuing to evaluate the variou